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Knockdown of aberrantly expressed nuclear
localized decorin attenuates tumour angiogenesis
related mediators in oral cancer progression
model in vitro
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Abstract
Background: Oral cancer accounts for roughly 3% of cancer cases in the world with about 350,000 newly reported
cases annually and a 5-year survival rate of only 50%. Majority of oral cancers are squamous cell carcinomas that
originate in the oral mucosal epithelial linings. We have previously shown that in human malignant squamous cells
carcinoma (SCC-25) as well as in dysplastic oral keratinocytes (DOK), a small leucine-rich multifunctional
proteoglycan decorin is aberrantly expressed and localized in the nucleus where it interacts with nuclear epidermal
growth factor receptor (EGFR). Post-transcriptional silencing of nuclear decorin significantly reduced IL-8 and IL8-
dependent migration and invasion in these dysplastic and malignant oral epithelia. The objective of this study was
to further examine the effects of nuclear decorin silencing on angiogenesis and angiogenesis related mediators in
this oral cancer progression cell line model.
Methods: We have used multiplex PCR, western blotting, and in vitro endothelial tube formation assay to study
angiogenesis and related pathways in nuclear decorin silenced (stable knockdown) DOK and SCC-25 cells.
Results: Nuclear decorin knockdown resulted in significant down regulation of IL-8 expression, however IL-10, and
TGF-β expression was not affected in either DOK or SCC25 cells as measured by multiplex RT PCR. IL-8 receptor
CXCR 1 and 2 expression was slightly lower in nuclear decorin silenced cells indicating a contributing mechanism in
previously shown reduced IL-8 mediated migration and invasion phenotype in these cells. IL-8 is known to induce
Matrix metalloproteinase 9 (MMP9) which not only plays a role in tumour migration and invasion but also induces
angiogenic switch. We found MMP9 to be significantly reduced in nuclear decorin silenced dysplastic and
malignant oral epithelia. Other potent angiogenic mediators, VEGF189 and ANG-1 were either significantly reduced
or completely abrogated in these cells. Angiogenesis as measured by endothelial tube-like formations of HUVEC
cells was reduced by almost 50 percent when HUVECs were incubated in the presence of conditioned medium
form nuclear decorin silenced dysplastic and malignant cell lines as compared to respective controls.
Conclusions: Together these results indicate that aberrantly expressed nuclear localized decorin strongly influences
angiogenic potential of dysplastic and malignant oral epithelial cells.
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Squamous cell carcinoma originating in the oral mucosal
linings, account for more than 90% of oral cavity cancers
[1,2]. The incidence of oral cancer, although not well
documented, is on the rise adding to the existing burden
due to widespread low survival and high recurrence
rates. Oral cancer makes up approximately 3% of all can-
cer cases [3] and is the 8th most common cancer in the
world among men and the 14th most common among
women [4]. The incidence rate of oral cancer is highest
in Pakistan, France, India, and Brazil [4] and it is respon-
sible for roughly 125,000 deaths annually of which an
estimated 95,000 occur in developing countries [3].
A critical step in the pathology of tumor progression is
angiogenesis; the generation of new blood vessels from
preexisting vessels, without which tumours cant grow be-
yond couple of mm in size. New blood vessels play a key
role in tumour growth by supplying oxygen and nutrients
to the tumour cells. Angiogenesis is a progressive physio-
logical process during which specific mechanisms are
induced to overcome the natural angiostatic state (in most
adult tissues) of the vasculature leading to the angiogenic
switch [5,6]. Some proteases such as matrix metalloprotei-
nase 9 (MMP-9) are known to induce this switch [7]. One
of the most potent mediator of angiogenesis is vascular
endothelial growth factor (VEGF); a highly specific mito-
gen for endothelial cells [8]. VEGF system is composed of
five isoforms created by alternative splicing of the VEGF
mRNA. The human VEGF proteins consist of 121, 145,
165, 189 and 206 amino acids (VEGF121, VEGF145,
VEGF165, VEGF189, and VEGF206). All isoforms contain
exons 1–5 and 8 and differ only by various combinations
of either no additional exon (VEGF121), or addition of exon
7 (VEGF165) or exon 6 and exon 7 (VEGF189) [9-11]. Aug-
mented endogenous VEGF expression has been shown in
various cancers and has been associated with poor progno-
sis and metastasis in oral squamous cell carcinoma [12].
Another important mediator of angiogenesis is angiopoie-
tin-1 (ANG-1). During the process of angiogenesis VEGF
and angiopoietins function in concert, with VEGF acting
early during vessel formation, and ANG-1 acting later dur-
ing vessel remodelling, maturation and stabilization [13].
In addition to well known role of controlling leukocyte
trafficking in homeostasis and inflammation[14], the chemo-
kines system also functions in tissue regulation outside the
hematopoietic compartment and is involved in angiogenesis,
tumour development, growth and metastasis [15,16]. Che-
mokine-mediated regulation of angiogenesis involves pro-
angiogenic chemokines CXCL8/IL8 [17,18] interacting with
CXCR2 receptor, and anti-angiogenic chemokines CXCL10/
IP10 [19,20] interacting with CXCR3 receptor. Chemokines
also regulate angiogenesis in a receptor-independent manner
by interfering with angiogenic function of VEGF and basic
fibroblast growth factor (bFGF) [21,22]. IL-8 is a very potentangiogenic chemokine and is known to play an important
role in cancer progression and metastasis [17,23,24]. IL-8
has been shown to be responsible for most of the angiogenic
activity induced by human oral squamous carcinoma cells
[25,26].
Previously, we have shown that multifunctional proteo-
glycan decorin is aberrantly expressed and localized in
the nucleus bound to nuclear epidermal growth factor
receptor (EGFR) in human dysplastic oral keratinocytes
(DOK) and malignant squamous carcinoma cells (SCC-
25) [27,28]. In an effort to examine the role of this nu-
clear localized decorin, we stably knocked down nuclear
decorin in this oral cancer cell line model. Post-tran-
scriptional nuclear decorin knock down resulted in sig-
nificantly reduced IL-8 and IL8-dependent migration
and invasion in these dysplastic and malignant oral epi-
thelia [28]. Since IL-8 is also a very potent proangiogenic
chemokine, in this current study we examined the effect
of nuclear decorin knockdown on angiogenesis and
angiogenesis related pathways.
Methods
Cell lines and culture conditions
Oral epithelial origin, premalignant- Dysplastic Oral Kera-
tinocytes (DOK) and malignant- Squamous Carcinoma
Cell (SCC-25) lines were routinely maintained in DMEM/
F12 (Hyclone, Logan, Utah) supplemented with 10% Foetal
Calf Serum for use as in vitro model in our studies, as
described previously [29,30]. Silencing of decorin gene ex-
pression was achieved using short hairpin RNA (shRNA)
technology as explained earlier [28]. Briefly, oligonucleo-
tides targeting decorin transcript variants A1 and A2 and
scrambled sequence control were custom synthesized,
annealed, and cloned into shRNA expression vector pGe-
neClip PuroTM (Promega) by Super Array Bioscience Cor-
poration (Frederick, MD). BLAST queries were performed
to ensure that the sequences have no significant homology
with any other human genes. Transformation grade
shRNAi plasmids were transfected into DOK and SCC-25
cells using Effectene™ transfection reagent following manu-
facturer’s protocol (Qiagen, Valencia, CA). The stable
transfectants were selected for puromycin (Calbiochem,
San Diego, CA) resistance at 2.5 μg/ml optimal concentra-
tion. Pools of stable transfectants (maintained at 1 μg/ml
of puromycin) were used in all experiments to avoid
clone-specific differences. Decorin knock down was con-
firmed at transcript and protein level by quantitative real-
time reverse transcription-PCR and Western blotting, re-
spectively. Pooled decorin-shRNA transfected DOK or
SCC-25 clones showed more than 80% reduction in dec-
orin mRNA expression and almost complete abrogation of
decorin protein expression in nuclear lysates and /or in
whole cell lysates when compared to control-shRNA
transfected clones or no transfection wild type DOK [28].
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ferred to as wild type (WT), scrambled shRNA stable trans-
fectants as control (or Ctrl-shRNA in figures), and decorin
shRNA stable transfectants as decorin silenced (or DCN-
shRNA in figures). WT, control, or decorin silenced DOK
and SCC-25 cells were cultured (5 x 105 cells/ well) in
complete medium for 24 h, conditioned medium (CM) was
harvested and was concentrated using a Centriplus™ centri-
fugal concentrator (Millipore, Bedford, Massachusetts).
Human umbilical vein endothelial cells (HUVECs)
(ATCC, Manassas, VA) were maintained in the endothe-
lial cell growth medium EGM-2 Bullet Kit W (Lonza,
Walkersville, Maryland). Culture medium was changed
every 2–3 days, and cells were passed when 90% conflu-
ence. Experiments were performed using cells between
passages 2 and 5. HUVECs were incubated in DMEM/
F12 supplemented with 10% FBS for 24 h before use in
tube formation angiogenesis assay.
Multiplex PCR
RNA was extracted from DOK and SCC-25 cells using
RNeasy Plus mini kit (Qiagen, Valencia, CA). cDNA was
synthesized from 2.5 μg of RNA using SuperScript™ III
Reverse Transcriptase (Invitrogen, San Diego, CA). The
expression levels of vascular endothelial growth factors
and its receptors (VEGF 165, VEGF 121, VEGF 189,
FLT1 and FLK1, Angiopoietin-1 & 2, and TIE-2), cyto-
kines (IL-8, IL-14, IL-10, IL-5, and TGFβ) and chemo-
kines receptors (CXCR1&2,CXCR4,) were measured in
decorin silenced, control, and WT cells using multiplex
PCR (MPCR) Kits for human VEGF and its receptors
set-3, human TH1/TH2 cytokines set-4 and human che-
mokines receptors CXCR set-1(MaximBiotech, San Fran-
cisco, CA) respectively.The PCR primers in theses kits
have similar Tm and no obvious 3'-end overlap to en-
hance multiple amplification in a single tube. The ex-
pression of the housekeeping gene, GAPDH, was also
measured in each reaction. MPCR was carried out
according to the manufacturer’s instructions. Briefly, 1X
MPCR buffer, 2.5 units of Taq DNA polymerase, and
cDNA template were mixed in a 25 ul reaction and sub-
jected to 35 cycles of PCR, with denaturing, annealing,
and extension temperatures at 96, 60, and 70°C, respect-
ively. Following MPCR, the DNA amplicons were frac-
tionated electrophoretically in 2% agarose gel containing
0.5 ug/mL ethidium bromide.
Western blot analysis
Cells were rinsed with ice-cold PBS and were lysed in a
buffer containing 20 mM Tris, pH 7.6, 0.1% SDS, 1% Tri-
ton-X, 1% deoxycholate, 100 μg/ml PMSF, and protease
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). Lysates
were centrifuged at 20,000 x g for 20 min at 4°C. Protein
concentration was determined by Bis-Cinchonic Acid(BCA) protein assay (Pierce, Rockford, IL) and subjected
to 10% SDS-PAGE analysis, followed by transfer to poly-
vinylidene difluoride membrane (Bio-Rad, Hercules, CA).
The membranes were immunoprobed with 1:1000 dilu-
tion of sheep polyclonal antibody to human MMP9
((Abcam, Cambridge, MA) or 1:1000 dilution of anti-
human β-tubulin polyclonal antibody. Western blots
were developed with appropriate horseradish peroxidase
conjugated secondary antibodies (Bio-Rad) and ECL Plus
chemiluminescence system (Amersham, Arlington
Heights, IL) and exposed to auto radiographic films.
In vitro angiogenesis assay
In Vitro angiogenesis was assessed using the endothelial
tube formation assay (Cell Biolabs, San Diego, CA) which
is based on the ability of endothelial cells to form three di-
mensional capillary-like tubular structures when cultured
on a gel of basement membrane extract. Manufacturer’s
instructions were followed to perform the assay. Briefly
ECM gel prepared from Engelbreth–Holm–Swarm (EHS)
tumour cells was thawed overnight at 4°C and mixed to
homogeneity using cooled pipette tips. Wells of pre-chilled
48 well cell culture plate were coated with a thin layer of
ECM gel (100 ul /well) and left to polymerize at 37°C for
60 min. HUVECs (3X104) in 150 ul medium were added
to each well along with 150 ul of either WT, control or
decorin silenced conditioned medium on solidified ECM
gel. The plate was incubated at 37°C for 18 h, and the
endothelial tubes were observed using a light microscope.
Three microscopic fields were selected at random and
photographed. Tube formation ability was quantified by
counting the total number of cell clusters and branching
under three X4 fields per well. The results were expressed
as mean of branching compared with the control groups.
Each experiment was performed at least twice.
Statistical analysis
Student’s paired t test was used to determine the statis-
tical significance of the data. Statistical analysis was per-
formed on Graph Pad Prism Software. Significance was
evaluated at p values:
* p <0.05, ** p <0.01, *** p <0.001.
Results
Effect of nuclear decorin silencing on cytokines/Chemokines
expression in dysplastic and malignant oral epithelia
To evaluate the effect of aberrantly expressed nuclear dec-
orin on the expression level of TGF-β, IL-10, and IL-8 sim-
ultaneously, DOK and SCC-25 WT, decorin silenced and
control cells were allowed to grow in culture for 24 h, RNA
was extracted and reverse transcribed to cDNA and sub-
jected to multiplex PCR. Compared with WT or control-
shRNA cells, decorin silenced DOK and SCC-25 cells did
Figure 1 Effect of nuclear decorin silencing on cytokines/chemokines expression in decorin silenced DOK and SCC-25 cells. DOK and
SCC-25 cells were stably transfected with decorin-shRNA (DCN-shRNA), or scrambled sequence-shRNA (Ctrl-shRNA) or no transfection control (WT).
RNA was extracted and cDNA was subjected to multiplex RT-PCR to detect multiple cytokine transcripts. MPCR products were fractionated
electrophoretically on a 2% agarose gel containing 0.5 mg/ml ethidium bromide, visualized under UV light and photographed. The results shown
are representative of three independent experiments.
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TGF-β. However, as we have previously shown [28] IL-8
expression was significantly reduced in decorin silenced
DOK or SCC-25 cells (Figure 1).
Nuclear decorin silencing down regulates IL-8 receptors in
DOK and SCC-25 cells
We determined the expression of IL-8 receptor (CXCR1&2)
along with other chemokines stromal cell-derived factor
(SDF-1) and their receptors (CXCR4) in a multiplex PCR
system. As shown in Figure 2, CXCR1&2 expression was
found to be slightly lower in decorin silenced dysplastic or
malignant epithelia in comparison to respective wild type
and control cells. The expression of CXCR4 was relatively
unaffected and its cognate ligand SDF-1/CXCL12 was not
expressed in these cancerous and dysplastic oral epithelial
cells.
Reduction of MMP9 protein expression in nuclear decorin
silenced DOK and SCC25 cells
Matrix metalloproteinase 9 is not only involved in cancer
cell migration and invasion but also triggers angiogenicFigure 2 Nuclear decorin silencing affects IL-8 receptor expression in
WT, control and decorin silenced DOK and SCC-25 cells and cDNA was sub
other receptors. MPCR products were fractionated electrophoretically on a
under UV light and photographed. The results shown are representative ofswitch [7] and hence plays a key role in tumour progres-
sion. Therefore, we sought to determine if nuclear dec-
orin silencing has an effect on MMP9 expression in
these dysplastic and malignant oral epithelial cells. Inter-
estingly, MMP9 protein expression was significantly
reduced in nuclear decorin-silenced DOK or SCC-25
cells as compared to control and WT cells when mea-
sured by western blotting (Figure 3).
Effect of nuclear decorin silencing on VEGF and
angiopoietin-1 expression in decorin silenced DOK and
SCC25 cells
The process of angiogenesis is tightly regulated and depends
on a dynamic balance between several mediators; vascular
endothelial growth factors and angiopoietins are two such
mediators. We determined the expression of these and
other angiogenesis related mediators in nuclear decorin
silenced dysplastic and malignant oral epithelial cells via
multiplex PCR assays. As shown in Figure 4, the expression
of ANG-1 was completely abrogated in decorin silenced
DOK or SCC-25 cells, where as VEGF189 expression was
significantly down regulated. However other VEGF splicedecorin silenced DOK and SCC-25 cells. RNA was extracted from
jected to multiplex RT-PCR to detect CXCR1&2 expressions along with
2% agarose gel containing 0.5 mg/ml ethidium bromide, visualized
three independent experiments.
Figure 3 MMP9 expression down regulation in decorin silenced
DOK and SCC25 cells. Cell lysates from decorin silenced and control
dysplastic and malignant oral epithelia were collected as described in
materials and methods and subjected to SDS-PAGE followed by
immunoblotting using anti-MMP9 and anti-β-tubulin antibodies. Data
shown from one representative experiment of three.
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(Figure 4). As expected, VEGF receptors FLT1 and FLK1
were not expressed by these oral epithelial cells, and only a
faint TIE2 (ANG-1 receptor) band was detected in both
DOK and SCC25 irrespective of nuclear decorin silencing.
ANG-2 was not expressed across the cell lines tested.
Decorin silencing attenuates the angiogenic potential of
dysplastic and malignant oral epithelial cells
Since nuclear decorin silencing resulted in down regulation
of a variety of proangiogenic mediators, we examined
whether decorin silencing has any effect on angiogenesis of
oral squamous cell carcinoma. An in vitro tube formation
assay using HUVECs was performed to mimic in vivo oralFigure 4 VEGF and ANG-1 expression modulation in decorin silenced
decorin silenced DOK and SCC-25 cells and cDNA was subjected to multipl
MPCR products were fractionated electrophoretically on a 2% agarose gel c
photographed. The results shown are representative of three independentsquamous cell carcinoma associated angiogenesis. We
observed a significant suppression of vessel-like structures,
consisting of elongations and alignment of the cells when
HUVECS were incubated with CM from either decorin-
silenced DOK or SCC-25 cells compared to respective WT
or control cells (Figure 5).
Discussion
Tumours require neovascularisation / angiogenesis to pro-
gress into clinically significant dimensions, and to
metastasize [31] . They need a microvasculature to deliver
micronutrients and oxygen to the growing tumour mass.
Studies have indicated that an increased angiogenesis
(microvascular density) correlates with poor outcomes in
several human tumours [32]. Mechanistically, tumour
angiogenesis involves proliferation and migration of vascu-
lar endothelial cells and their organization into tumour
associated blood vessels. Several mediators of angiogenesis
have been identified including VEGF, FGF, and IL8. Under
normal conditions, a steady equilibrium is vigilantly main-
tained between proangiogenic and antiangiogenic media-
tors. Tumour cells acquire the ability to sustain
angiogenesis by aberrant production of angiogenic or anti-
angiogenic factors during transition to the malignant
phenotype [33].
IL-8 is a potent angiogenic factor that plays an important
role in cancer progression and metastasis [17,23,24]. Im-
portantly, it has been demonstrated that IL-8 is responsible
for most of the angiogenic activity induced by human oral
squamous carcinoma cells [25,26]. IL-8 (CXCL-8) is a
member of the CXC chemokines family and IL-8 receptors
CXCR1 and CXCR2 are expressed on various normal and
cancerous cells including head and neck squamous cellDOK and SCC25 cells. RNA was extracted from WT, control and
ex RT-PCR to detect the expression of angiogenesis related mediators.
ontaining 0.5 mg/ml ethidium bromide, visualized under UV light and
experiments.
Figure 5 Overall influence of nuclear decorin silencing on angiogenic capacity of DOK and SCC-25 cell derived factors; as assessed on
human endothelial cells in vitro. A, HUVECs (3X104) were plated on ECM coated wells along with 150 ul of either WT, control or decorin
silenced conditioned medium (CM). Endothelial tube formation was assessed after incubating at 37°C for 18 h, using a light microscope. Three
microscopic fields were selected at random and photographed at 200x magnification. B, Tube formation ability was quantified by counting the
total number of cell clusters and branching under three fields per well. The results are expressed as mean of branching compared with the
control groups. Each experiment was performed at least twice. Numbers represent mean± SD of three individual experiments. ** p <0.01,
*** p <0.001 compared to respective controls.
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mediated angiogenesis, though not fully understood but is
quite elaborated. Besides tumor cells, IL-8 and its receptors
CXCR1 and CXCR2 have been observed on endothelial
cells [24,37] and have been shown to play a role in endo-
thelial cell proliferation [17]. A more direct role of IL-8 in
angiogenesis by enhancing proliferation and survival and
inhibiting apoptosis of CXCR1- and CXCR2-expressing
endothelial cells have been described. Furthermore, treat-
ment of endothelial cells with IL-8 significantly enhanced
production of MMP9 and capillary tube organization [38].
We have previously shown that nuclear decorin interacts
with nuclear localized EGFR in dysplastic and malignant
oral epithelial cells. We have also shown that nucleardecorin knockdown significantly reduces IL-8 production
in these cells. Interestingly, EGFR (trans) activation has
been shown to mediate IL-8 production in epithelial cells
[39,40].
As mentioned above, angiogenesis is a complex multi-
stage process. Two important steps are endothelial cell pro-
liferation and migration by degradation of the extracellular
matrix by matrix metalloproteinase [41] and capillary tube
formation mediated by various angiogenic factors such as
vascular endothelial growth factor, basic fibroblast growth
factor, and IL-8 [42]. Recent reports suggest that in addition
to cell proliferation and migration, endothelial cell survival
and death are also important components for tumor angio-
genesis which is in part mediated by vascular endothelial
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tein Bcl-2 [43]. A cell cycle-regulated apoptosis inhibitor,
survivin and the cell death-related gene family, Bcl-2 are
associated with VEGF-induced angiogenesis [44].
Angiopoietin 1 (ANG-1) promotes angiogenesis by en-
hancing migration and proliferation of endothelial cells
[45]. More recently, it has been shown that this positive ef-
fect of ANG-1 on endothelial cell migration and prolifera-
tion is mediated, in part, by the production of IL-8, which
by acting in an autocrine fashion suppresses apoptosis and
facilitates endothelial cell proliferation and migration [46].
Our current study indicates that a myriad of proteins
get affected upon nuclear decorin silencing in dysplastic
and malignant oral epithelial cells, including IL-8, IL-8
receptors, MMP9, VEGF, and ANG-1. Interestingly many
of these proteins are linked to IL-8(in one way or an-
other) which is a very potent angiogenic factor especially
in oral squamous cell carcinoma [25]. As we have indi-
cated before [28], nuclear decorin perhaps effects IL-8
production through its direct or indirect interactions
with other normal or aberrant nuclear proteins such as
nuclear epidermal growth factor receptors in dysplastic
and malignant oral epithelial cells. Our recently pub-
lished and current results also indicate that IL-8 activity
in tumour and tumour microenvironment contributes to
oral cancer progression through its functions in the
regulation of angiogenesis, tumour cell invasion and
metastasis.
Conclusions
We have used in vitro stable gene silencing in human
dysplastic and malignant oral epithelial cells to study the
role of nuclear localized decorin in oral cancer angiogen-
esis. We demonstrate that nuclear localized decorin
knockdown significantly inhibits major proangiogenic
mediators such as IL-8, MMP9, ANG-1 and VEGF. The
decreased expression of these angiogenesis mediators
correlated with decreased vascularization capacity
in vitro. These findings suggest that nuclear decorin si-
lencing may suppress the angiogenesis of oral squamous
cell carcinoma by inhibiting the expression of certain
proangiogenic mediators, in particular IL-8.
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